Switch theme
Sign up to access all valuation multiples
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
1992
260
LTM Revenue $75.0M
LTM EBITDA -$43.2M
$246M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AVITA Medical has a last 12-month revenue of $75.0M and a last 12-month EBITDA of -$43.2M.
In the most recent fiscal year, AVITA Medical achieved revenue of $64.3M and an EBITDA of -$55.3M.
AVITA Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AVITA Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.1M | $64.3M | XXX | XXX | XXX |
| Gross Profit | $28.4M | $42.4M | XXX | XXX | XXX |
| Gross Margin | 57% | 66% | XXX | XXX | XXX |
| EBITDA | -$33.5M | -$55.3M | XXX | XXX | XXX |
| EBITDA Margin | -67% | -86% | XXX | XXX | XXX |
| Net Profit | -$26.7M | -$35.4M | XXX | XXX | XXX |
| Net Margin | -53% | -55% | XXX | XXX | XXX |
| Net Debt | n/a | $17.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, AVITA Medical's stock price is $9.
AVITA Medical has current market cap of $236M, and EV of $246M.
See AVITA Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $246M | $236M | XXX | XXX | XXX | XXX | $-2.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, AVITA Medical has market cap of $236M and EV of $246M.
AVITA Medical's trades at 3.3x LTM EV/Revenue multiple, and -5.7x LTM EBITDA.
Analysts estimate AVITA Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for AVITA Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $246M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | -4.4x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAVITA Medical's NTM/LTM revenue growth is 53%
AVITA Medical's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, AVITA Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate AVITA Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for AVITA Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -86% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 65% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 91% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 52% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 174% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AVITA Medical acquired XXX companies to date.
Last acquisition by AVITA Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . AVITA Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was AVITA Medical founded? | AVITA Medical was founded in 1992. |
| Where is AVITA Medical headquartered? | AVITA Medical is headquartered in United States of America. |
| How many employees does AVITA Medical have? | As of today, AVITA Medical has 260 employees. |
| Who is the CEO of AVITA Medical? | AVITA Medical's CEO is Mr. James M. Corbett. |
| Is AVITA Medical publicy listed? | Yes, AVITA Medical is a public company listed on NAS. |
| What is the stock symbol of AVITA Medical? | AVITA Medical trades under RCEL ticker. |
| When did AVITA Medical go public? | AVITA Medical went public in 2012. |
| Who are competitors of AVITA Medical? | Similar companies to AVITA Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of AVITA Medical? | AVITA Medical's current market cap is $236M |
| What is the current revenue of AVITA Medical? | AVITA Medical's last 12-month revenue is $75.0M. |
| What is the current EBITDA of AVITA Medical? | AVITA Medical's last 12-month EBITDA is -$43.2M. |
| What is the current EV/Revenue multiple of AVITA Medical? | Current revenue multiple of AVITA Medical is 3.3x. |
| What is the current EV/EBITDA multiple of AVITA Medical? | Current EBITDA multiple of AVITA Medical is -5.7x. |
| What is the current revenue growth of AVITA Medical? | AVITA Medical revenue growth between 2023 and 2024 was 28%. |
| Is AVITA Medical profitable? | Yes, AVITA Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
